IP Library Granted Patent US 8,399,249
Granted Patent B2
US 8,399,249 · App. 12/389,265 · Granted Mar 19, 2013

Procedure for the generation of a high producer cell line for the expression of a recombinant anti-CD34 antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,399,249
App. No.
12/389,265
Granted
Mar 19, 2013
Kind
B2
Abstract

The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines.

Claims (10)

1. A method for generation of a high producer cell line expressing a recombinant anti-CD34 antibody comprising the amino acid sequences set forth in SEQ ID NOS:2 and 4, wherein the method comprises the following steps:

(a) selecting cell clones expressing high amounts of the antibody and

(b) analyzing the expressed antibodies produced from cell clones in a cell capture assay for binding to CD34 + cells, wherein the capture assay comprises

(i) incubating the recombinant anti-CD34 antibody attached to a microplate with cells that express CD34; and

(ii) determining the level of binding of CD34 + cells to the anti-CD34 antibody.

2. The method according to claim 1 , wherein the antibody is expressed in HEK293T or CHO cells.

3. The method according to claim 2 , wherein the cells are adapted to protein free medium.

4. The method according to claim 2 , wherein the cells are directly grown in protein free medium.

5. The method according to claim 1 , wherein the cell capture assay is a dose response cell capture assay.

6. The method according to claim 1 , wherein in that the cell capture assay is a competition cell capture assay.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036367/0652 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036375/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2009
From: KERSCHBAUMER, RANDOLF; BOECK-TAFERNER, PETRA; SCHEIFLINGER, FRIEDRICH
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 022864/0448 →